Clinical Applications of Assisted Oocyte Activation in Couples with Various Reproductive Problems: A Systematic Review

other OA: closed public-domain-us
View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-10 ⓘ

This systematic review of 30 studies evaluated assisted oocyte activation for various infertility disorders, finding that while it may overcome fertilization failure, insufficient evidence limits definitive conclusions on its efficacy or safety.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ICSI may face fertilization failure, prompting the use of assisted oocyte activation (AOA) techniques. While AOA is implemented in infertility clinics, its target patients and definitive application remain uncertain. This systematic review adheres to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to assess reproductive outcomes in ICSI-AOA cycles compared to conventional ICSI and evaluate AOA effectiveness in various infertility disorders. A literature search encompassed PubMed, Web of Science, EMBASE, and Scopus databases until December 2023 for relevant English studies. Included studies compared ICSI-AOA with conventional ICSI in couples with prior fertilization failure, utilizing diverse AOA methods. Control groups consisted of sibling oocytes, previous cycles of the same couples, or couples undergoing conventional ICSI. Evaluated outcomes included fertilization, cleavage, embryo quality, implantation, pregnancy, and live birth rates. Article screening and data extraction were performed by two authors, with risk of bias assessed by another investigator. Out of 3088 initially identified articles, 30 studies were included, focusing on fertilization failure (n = 10), female infertility (n = 3), PLCζ defects (n = 4), poor sperm quality (n = 4), Globozoospermia (n = 4), and surgically retrieved sperm (n = 8). Most studies concluded that AOA could overcome fertilization failure, but success rates varied based on sperm-related or oocyte-related factors in ICSI-AOA cycles. Due to differences in patient inclusion criteria and sample sizes, most studies were not sufficiently similar for pooled analysis, limiting robust conclusions. There is insufficient evidence, particularly from randomized controlled trials (RCTs), to determine the efficacy or safety of ICSI-AOA as a treatment strategy. Registration number is PROSPERO, CRD42024551221.

My notes (saved in your browser only)

MeSH descriptors

Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic Sperm Injections, Intracytoplasmic

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-09-20T09:27:46.357103+00:00
pubmed
last seen: 2026-09-25T06:08:17.724223+00:00
unpaywall
last seen: 2026-09-25T06:33:09.130943+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine